On July 29, Humana fell 6.1% in pre-market trading, trading at $357.6/share, with turnover of $452,800. The decline came immediately after the company released its second-quarter fiscal results.

Humana officially reported Q2 earnings and reaffirmed its full-year adjusted financial guidance without revising its annual adjusted EPS or revenue range. Ahead of the report, consensus estimates projected quarterly revenue of $40.611 billion, representing 27.33% year-over-year growth, and adjusted EPS of $7.22, up 21.97% year-over-year. During Q1, the company had posted revenue of $39.648 billion with adjusted EPS of $10.31, which beat estimates but reflected a 10.97% decline from the prior year. The company had previously guided for full-year adjusted earnings of at least $9 per share. The pre-market decline suggests investors may have found the unchanged outlook insufficient given elevated expectations around cost trends and membership growth metrics, particularly as the company continues to navigate headwinds from lower Medicare Advantage star ratings impacting bonus revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)